Literature DB >> 1772779

Chromosome 17- and p53 changes in lymphoma.

M A Rodriguez1, R J Ford, A Goodacre, P Selvanayagam, F Cabanillas, A B Deisseroth.   

Abstract

The clinical course of lymphoma patients in whom rearrangements or deletions of the short arm of chromosome 17 (17p) were evident by cytogenetics was rapidly progressive with a short survival. The gene for the protein designated p53 resides in 17p. We studied four lymphoma cell lines derived from human tumours, and 25 tumour samples of patients with lymphomas, for any evidence of p53 genomic changes by Southern blot technique. The four cell lines and four of the 25 tumour samples showed numerical changes of chromosome 17 or structural abnormalities of 17p (translocations or deletions). Allelic loss of the p53 gene was found in two of the four cell lines, and one of these in addition showed a rearrangement of the 3' end of the gene. Of the four tumours known to have chromosome 17 abnormality, one specimen showed allelic loss of the p53 gene. None of the remaining tumour samples showed any significant change. These studies suggest that acquisition of changes in the short arm of chromosome 17, which may be interrelated with the p53 gene, may carry a poor prognosis in patients with non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772779     DOI: 10.1111/j.1365-2141.1991.tb08084.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

2.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time.

Authors:  M A Piris; F Pezzella; J C Martinez-Montero; J L Orradre; R Villuendas; M Sanchez-Beato; R Cuena; M A Cruz; B Martinez; F ] Pezella F [corrected to Pezzella
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.